Viral Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Growth Factors of Viral Vaccines Market
The global viral vaccines market is witnessing robust expansion, driven by increasing prevalence of infectious diseases, growing global immunization coverage, and a significant surge in R&D investments. According to Fortune Business Insights, the global viral vaccines market size was valued at USD 61.04 billion in 2023. This market is projected to grow from USD 64.62 billion in 2024 to USD 100.67 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.7% during the forecast period.
The growth of the viral vaccines market is propelled by widespread global initiatives targeting the eradication of infectious viral diseases such as measles, hepatitis, influenza, HIV, and, more recently, COVID-19. Continuous research to develop safer, more effective, and longer-lasting vaccines plays a key role in shaping the trajectory of this market.
Key Growth Drivers
One of the major factors fueling the demand for viral vaccines is the escalating incidence of viral infections worldwide. The global outbreak of COVID-19 not only underlined the importance of vaccine readiness but also dramatically increased vaccine production capacities, expedited regulatory pathways, and catalyzed public and private investments. These developments are expected to have a lasting positive impact on the vaccine industry.
Moreover, increased awareness among consumers and governments regarding the benefits of preventive healthcare is encouraging higher vaccine uptake, especially in pediatric and adult immunization schedules. Organizations such as GAVI (Global Alliance for Vaccines and Immunization) and the WHO (World Health Organization) have played a pivotal role in expanding vaccine access in low- and middle-income countries, which significantly contributes to global demand.
Technological advancements have also been instrumental in this growth. Platforms such as mRNA, DNA, viral vector, and recombinant vaccines are revolutionizing vaccine development by enabling faster production timelines, improved safety profiles, and scalable manufacturing capabilities.
Segmentation Overview
The viral vaccines market is segmented based on type, route of administration, age group, end-user, and region.
By Type: The market includes live-attenuated vaccines, inactivated vaccines, recombinant vaccines, and others. Recombinant vaccines are gaining significant traction due to their enhanced safety and stability.
By Route of Administration: Includes injectable and oral vaccines. Injectable vaccines dominate due to broader applicability across all age groups.
By Age Group: The market is segmented into pediatric and adult, with the pediatric segment accounting for a dominant share due to national immunization schedules and early-life vaccine mandates.
By End-User: Comprises hospitals, clinics, vaccination centers, and others. Hospitals and government vaccination centers are the leading end-users owing to widespread accessibility.
Regional Insights
North America held the largest share of the global viral vaccines market in 2023. The region benefits from well-established healthcare infrastructure, high vaccine awareness, and government-backed immunization programs. The United States continues to lead the market with robust investments in vaccine research, procurement, and administration.
Europe follows closely, driven by public health awareness and universal healthcare policies supporting vaccine coverage. Countries such as Germany, France, and the U.K. are central to regional growth.
Asia Pacific is poised for the fastest growth, especially due to rising populations, expanding healthcare systems, and government efforts to promote vaccination. India and China are at the forefront of this growth, both as major markets and manufacturing hubs.
Competitive Landscape
The global viral vaccines market is moderately consolidated, with several global and regional players. Leading companies include:
GlaxoSmithKline plc
Pfizer Inc.
Merck & Co., Inc.
Sanofi
Johnson & Johnson
AstraZeneca
Bharat Biotech
Serum Institute of India
CSL Limited
Moderna, Inc.
These companies focus on strategic partnerships, vaccine innovations, capacity expansion, and global distribution to strengthen their market positions. mRNA vaccine developers, in particular, have gained strong traction post-COVID-19.
Conclusion
With increasing disease burdens, growing awareness, and rapid advances in biotechnology, the global viral vaccines market is set to experience sustained growth in the coming years. The push for universal vaccination and emerging technologies will play a crucial role in shaping the future of the vaccine landscape worldwide.
ATTRIBUTE DETAILS
Study Period 2019-2030
Base Year 2022
Estimated Year 2023
Forecast Period 2023-2030
Historical Period 2019-2021
Growth Rate CAGR of 4.4% from 2023 to 2030
Unit Value (USD Billion)
Segmentation By Form
Liquid
Lyophilized
By Container Format
Vials
Prefilled Syringes
By Biosafety Level Type
Biosafety Level 1
Biosafety Level 2
Biosafety Level 3
Biosafety Level 4
By Region
North America (By Form, Container Format, Biosafety Level Type, and Country)
U.S.
Canada
Europe (By Form, Container Format, Biosafety Level Type, and Country/Sub-Region)
U.K.
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
Asia Pacific (By Form, Container Format, Biosafety Level Type, and Country/Sub-Region)
Japan
China
India
Australia
South Korea
Rest of Asia Pacific
Rest of the World (By Form, Container Format, and Biosafety Level Type)
Please Note:
It will take 5-6 business days to complete the report upon order confirmation.
The global viral vaccines market is witnessing robust expansion, driven by increasing prevalence of infectious diseases, growing global immunization coverage, and a significant surge in R&D investments. According to Fortune Business Insights, the global viral vaccines market size was valued at USD 61.04 billion in 2023. This market is projected to grow from USD 64.62 billion in 2024 to USD 100.67 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.7% during the forecast period.
The growth of the viral vaccines market is propelled by widespread global initiatives targeting the eradication of infectious viral diseases such as measles, hepatitis, influenza, HIV, and, more recently, COVID-19. Continuous research to develop safer, more effective, and longer-lasting vaccines plays a key role in shaping the trajectory of this market.
Key Growth Drivers
One of the major factors fueling the demand for viral vaccines is the escalating incidence of viral infections worldwide. The global outbreak of COVID-19 not only underlined the importance of vaccine readiness but also dramatically increased vaccine production capacities, expedited regulatory pathways, and catalyzed public and private investments. These developments are expected to have a lasting positive impact on the vaccine industry.
Moreover, increased awareness among consumers and governments regarding the benefits of preventive healthcare is encouraging higher vaccine uptake, especially in pediatric and adult immunization schedules. Organizations such as GAVI (Global Alliance for Vaccines and Immunization) and the WHO (World Health Organization) have played a pivotal role in expanding vaccine access in low- and middle-income countries, which significantly contributes to global demand.
Technological advancements have also been instrumental in this growth. Platforms such as mRNA, DNA, viral vector, and recombinant vaccines are revolutionizing vaccine development by enabling faster production timelines, improved safety profiles, and scalable manufacturing capabilities.
Segmentation Overview
The viral vaccines market is segmented based on type, route of administration, age group, end-user, and region.
By Type: The market includes live-attenuated vaccines, inactivated vaccines, recombinant vaccines, and others. Recombinant vaccines are gaining significant traction due to their enhanced safety and stability.
By Route of Administration: Includes injectable and oral vaccines. Injectable vaccines dominate due to broader applicability across all age groups.
By Age Group: The market is segmented into pediatric and adult, with the pediatric segment accounting for a dominant share due to national immunization schedules and early-life vaccine mandates.
By End-User: Comprises hospitals, clinics, vaccination centers, and others. Hospitals and government vaccination centers are the leading end-users owing to widespread accessibility.
Regional Insights
North America held the largest share of the global viral vaccines market in 2023. The region benefits from well-established healthcare infrastructure, high vaccine awareness, and government-backed immunization programs. The United States continues to lead the market with robust investments in vaccine research, procurement, and administration.
Europe follows closely, driven by public health awareness and universal healthcare policies supporting vaccine coverage. Countries such as Germany, France, and the U.K. are central to regional growth.
Asia Pacific is poised for the fastest growth, especially due to rising populations, expanding healthcare systems, and government efforts to promote vaccination. India and China are at the forefront of this growth, both as major markets and manufacturing hubs.
Competitive Landscape
The global viral vaccines market is moderately consolidated, with several global and regional players. Leading companies include:
GlaxoSmithKline plc
Pfizer Inc.
Merck & Co., Inc.
Sanofi
Johnson & Johnson
AstraZeneca
Bharat Biotech
Serum Institute of India
CSL Limited
Moderna, Inc.
These companies focus on strategic partnerships, vaccine innovations, capacity expansion, and global distribution to strengthen their market positions. mRNA vaccine developers, in particular, have gained strong traction post-COVID-19.
Conclusion
With increasing disease burdens, growing awareness, and rapid advances in biotechnology, the global viral vaccines market is set to experience sustained growth in the coming years. The push for universal vaccination and emerging technologies will play a crucial role in shaping the future of the vaccine landscape worldwide.
ATTRIBUTE DETAILS
Study Period 2019-2030
Base Year 2022
Estimated Year 2023
Forecast Period 2023-2030
Historical Period 2019-2021
Growth Rate CAGR of 4.4% from 2023 to 2030
Unit Value (USD Billion)
Segmentation By Form
Liquid
Lyophilized
By Container Format
Vials
Prefilled Syringes
By Biosafety Level Type
Biosafety Level 1
Biosafety Level 2
Biosafety Level 3
Biosafety Level 4
By Region
North America (By Form, Container Format, Biosafety Level Type, and Country)
U.S.
Canada
Europe (By Form, Container Format, Biosafety Level Type, and Country/Sub-Region)
U.K.
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
Asia Pacific (By Form, Container Format, Biosafety Level Type, and Country/Sub-Region)
Japan
China
India
Australia
South Korea
Rest of Asia Pacific
Rest of the World (By Form, Container Format, and Biosafety Level Type)
Please Note:
It will take 5-6 business days to complete the report upon order confirmation.
Table of Contents
124 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. New Product Launches, By Key Players
- 4.2. Key Industry Developments: Mergers, Acquisitions, and Partnerships
- 4.3. Epidemiology: Key Viral Diseases, By Key Countries, 2022
- 4.4. Pipeline Analysis, By Key Players
- 4.5. Impact of COVID-19 on the Market
- 5. Global Viral Vaccines Market Analysis, Insights and Forecast, 2019-2030
- 5.1. Market Analysis, Insights and Forecast – By Form
- 5.1.1. Liquid
- 5.1.2. Lyophilized
- 5.2. Market Analysis, Insights and Forecast – By Container Format
- 5.2.1. Vials
- 5.2.2. Prefilled Syringes
- 5.3. Market Analysis, Insights and Forecast – By Biosafety Level Type
- 5.3.1. Biosafety Level 1
- 5.3.2. Biosafety Level 2
- 5.3.3. Biosafety Level 3
- 5.3.4. Biosafety Level 4
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
- 6. North America Viral Vaccines Market Analysis, Insights and Forecast, 2019-2030
- 6.1. Market Analysis, Insights and Forecast – By Form
- 6.1.1. Liquid
- 6.1.2. Lyophilized
- 6.2. Market Analysis, Insights and Forecast – By Container Format
- 6.2.1. Vials
- 6.2.2. Prefilled Syringes
- 6.3. Market Analysis, Insights and Forecast – By Biosafety Level Type
- 6.3.1. Biosafety Level 1
- 6.3.2. Biosafety Level 2
- 6.3.3. Biosafety Level 3
- 6.3.4. Biosafety Level 4
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe Viral Vaccines Market Analysis, Insights and Forecast, 2019-2030
- 7.1. Market Analysis, Insights and Forecast – By Form
- 7.1.1. Liquid
- 7.1.2. Lyophilized
- 7.2. Market Analysis, Insights and Forecast – By Container Format
- 7.2.1. Vials
- 7.2.2. Prefilled Syringes
- 7.3. Market Analysis, Insights and Forecast – By Biosafety Level Type
- 7.3.1. Biosafety Level 1
- 7.3.2. Biosafety Level 2
- 7.3.3. Biosafety Level 3
- 7.3.4. Biosafety Level 4
- 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
- 8. Asia Pacific Viral Vaccines Market Analysis, Insights and Forecast, 2019-2030
- 8.1. Market Analysis, Insights and Forecast – By Form
- 8.1.1. Liquid
- 8.1.2. Lyophilized
- 8.2. Market Analysis, Insights and Forecast – By Container Format
- 8.2.1. Vials
- 8.2.2. Prefilled Syringes
- 8.3. Market Analysis, Insights and Forecast – By Biosafety Level Type
- 8.3.1. Biosafety Level 1
- 8.3.2. Biosafety Level 2
- 8.3.3. Biosafety Level 3
- 8.3.4. Biosafety Level 4
- 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-Region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. South Korea
- 8.4.6. Rest of Asia Pacific
- 9. Rest of the World Viral Vaccines Market Analysis, Insights and Forecast, 2019-2030
- 9.1. Market Analysis, Insights and Forecast – By Form
- 9.1.1. Liquid
- 9.1.2. Lyophilized
- 9.2. Market Analysis, Insights and Forecast – By Container Format
- 9.2.1. Vials
- 9.2.2. Prefilled Syringes
- 9.3. Market Analysis, Insights and Forecast – By Biosafety Level Type
- 9.3.1. Biosafety Level 1
- 9.3.2. Biosafety Level 2
- 9.3.3. Biosafety Level 3
- 9.3.4. Biosafety Level 4
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis (2022)
- 10.2. Company Profiles
- 10.2.1. Merck & Co., Inc.
- 10.2.1.1. Overview
- 10.2.1.2. Products
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. Financials (Based on Availability)
- 10.2.2. GSK plc
- 10.2.2.1. Overview
- 10.2.2.2. Products
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Sanofi
- 10.2.3.1. Overview
- 10.2.3.2. Products
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Pfizer Inc.
- 10.2.4.1. Overview
- 10.2.4.2. Products
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. Financials (Based on Availability)
- 10.2.5. SEQIRUS (CSL Limited)
- 10.2.5.1. Overview
- 10.2.5.2. Products
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Strategies
- 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Moderna, Inc.
- 10.2.6.1. Overview
- 10.2.6.2. Products
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Strategies
- 10.2.6.6. Financials (Based on Availability)
- 10.2.7. AstraZeneca
- 10.2.7.1. Overview
- 10.2.7.2. Products
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Strategies
- 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Johnson & Johnson Services, Inc.
- 10.2.8.1. Overview
- 10.2.8.2. Products
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Strategies
- 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Novavax
- 10.2.9.1. Overview
- 10.2.9.2. Products
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Strategies
- 10.2.9.6. Financials (Based on Availability)
- 10.2.10. Dynavax Technologies
- 10.2.10.1. Overview
- 10.2.10.2. Products
- 10.2.10.3. SWOT Analysis
- 10.2.10.4. Recent Developments
- 10.2.10.5. Strategies
- 10.2.10.6. Financials (Based on Availability)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
